Table 1.

Baseline characteristics of study groups with T1D and incidence of CKD≥3 during follow-up according to cohort

VariableFirst Joslin Kidney Study (n=275)Second Joslin Kidney Study (n=353)P Valuea
Study characteristics
 albuminuria categoryMAHigh NA or MA
 calendar years of recruitment1991–19922003–2005
 follow-up interval (yr)10-125-7<0.0001
Patient characteristics
 men (%) 51530.61
 age (yr)31±839±12<0.0001
 body mass index (kg/m2)25±427±5<0.0001
 systolic BP (mmHg)122±14121±130.45
 diastolic BP (mmHg)76±873±8<0.0001
 serum cholesterol (mg/dl)200±42187±30<0.0001
 ever smoking (%)51440.10
 age at diabetes diagnosis (yr)14±818±11<0.0001
 diabetes duration (yr)18±921±9<0.0001
 HbA1c (%)8.9±1.58.4±1.3<0.0001
 AER (μg/min)56 (37, 101)41 (24, 79)0.07
 eGFRcystatin (ml/min per 1.73 m2)133±30129±300.06
 treated with RASi/AHTN (%)3458<0.0001
Markers at baseline (pg/mL)
 free TNFα4.2 (3.2, 5.4)5.0 (3.4, 6.7)0.30
 total TNFα8.7 (5.7, 12.2)8.9 (4.9, 13.5)0.08
 TNFR11345 (1156, 1598)1382 (1180,1709)0.17
 TNFR22161 (1732, 2673)2230 (1869, 2695)0.12
Incidence of CKD≥3
 rate per 1000 person-years (95% CI) 15 (11–21)17 (12–24)
 cases (n)38310.05
  • Data expressed with a plus/minus sign are the mean ± SD. Markers at baseline are expressed as the median (25th, 75th percentiles). MA, microalbuminuria; NA, normoalbuminuria; NS, nonsignificant; RASi/AHTN, renin-angiotensin system inhibitors and/or other antihypertensive agent.

  • a Bonferroni correction was applied.